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INTRODUCTION                                                                   
The myocardium secretes various natriuretic peptides, such as atrial 
natriuretic peptide (ANP) and brain natriuretic peptide (BNP). BNP is 
secreted as pro-BNP, which is broken down to BNP and N-terminal 
proBNP (NT-proBNP) in equimolar amounts.(1) The secretion of BNP 
and NT-proBNP increases in a myocardium under strain, such as in 
heart failure. The relationship of increased serum BNP and NT-proBNP 
levels to ventricular decompensation is now an established concept, 
and their measurement has become a valuable laboratory tool in 
distinguishing heart failure from pulmonary disease in patients presenting 
with dyspnea.(2) LV function is an important determinant of outcome in 
patients with heart valve lesions. The relationship between serum BNP 
and NT-proBNP levels and ventricular function in patients with heart 
valve lesions is a new and evolving topic, but clinically valuable 
information has already emerged. 
BASIC CONCEPTS ABOUT NATRIURETIC PEPTIDES 
AND THE MYOCARDIUM
Brain natriuretic peptide (BNP) was fi rst isolated from porcine brain, 
but was later found to be secreted mainly by the myocardium. BNP 
belongs to a family of peptides that also includes atrial natriuretic 
peptide (ANP), c-type natriuretic peptide and urodilatin.(3) These 
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Serum levels of natriuretic peptides (BNP 
and NT- proBNP) are known to increase in cardiac failure, and 
aid in the diagnosis and management of such patients. BNP 
and NT-proBNP also increase in patients with heart valve 
lesions, and may contribute to the assessment and 
management of these patients. There appears to be a general 
trend towards higher BNP values in more severe heart valve 
lesions, but the exact implication of a raised BNP or NT-
proBNP appears to be different for each specifi c valve lesion. 
In aortic valve stenosis increased levels of BNP/NT-proBNP 
correlate with the degree of stenosis, symptoms and prognosis. 
In addition, the increased natriuretic peptide levels seem to 
refl ect left ventricular dysfunction, as high levels predict poor 
long-term outcomes in conservatively treated patients as 
well as post-operative death and poor functional recovery in 
those who survive the valve replacement procedure. 
In mitral regurgitation natriuretic peptide levels correlate 
with the degree of valvular regurgitation, and seem to refl ect 
subclinical left ventricular dysfunction. Serum natriuretic 
peptide levels are elevated in patients with mitral stenosis, 
and correlate with the degree of valvular stenosis and 
increased pulmonary pressure. 
Serum levels of natriuretic peptides are elevated in other 
heart valve lesions, such as aortic valve regurgitation, as well 
as different forms of mixed valvular disease, but very little is 
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known about the relationship between the serum levels of 
natriuretic peptides and the latter valve lesions. 
The practical application of our knowledge concerning serum 
natriuretic peptides and heart valve disease is limited at this 
stage, and no specifi c cut-off values to guide patient 
management have been incorporated into any offi cial 
guidelines as yet. This review aims to summarise current 
knowledge on serum BNP and NT–proBNP levels in patients 
with heart valve disease. The impact of this information on 
current clinical decision making in patients with different 
heart valve lesions, as well as evolving concepts concerning its 
potential future use, will be discussed.
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peptides share a common structure of a 17 amino acid ring and disulfi de 
bridge between two cysteine molecules. BNP is not stored in the 
myocardium, but rapid gene transcription followed by synthesis of the 
prehormone (proBNP) occurs in response to an increase in wall stress, 
mainly stretching of the myocardium. ProBNP consists of 108 amino 
acids, and is cleaved into equimolar amounts of the biologically active 
BNP (32 amino acids) containing the C-terminal fragment, and the 
biologically inactive N-terminal fragment, NT-proBNP, consisting of 76 
amino acids.
The biological effects of BNP are mediated by cyclic GMP (cGMP), 
which is formed upon binding of the ligand to its receptor, and include 
natriuresis, diuresis, peripheral vasodilatation and inhibition of the renin-
angiotensin aldosterone system. BNP has a half-life of 20 minutes, and 
is cleared through proteolysis by neutral endopeptidases. NT-proBNP 
has a half-life of 120 minutes and is cleared by renal excretion. 
Accordingly, the serum levels of NT-proBNP are about 6 times higher 
than those of BNP.
Assays for the determination of serum levels of both BNP and NT-
proBNP are commercially available (AxSYM BNP, Abbott; Elecsys NT-
proBNP, Roche Diagnostics). The advantage of assaying NT-proBNP is 
that it is more stable than BNP.  In the absence of additives NT-proBNP 
is stable at room temperature for 72 hours, whereas BNP is stable for 
24 hours in the presence of EDTA. In serum frozen at -20 or -70 
degrees Celsius it is stable for several months to a year.
FACTORS THAT INCREASE SERUM LEVELS OF BNP 
AND NT–proBNP
The main interest in serum BNP and NT-proBNP stems from the 
observation that their levels are increased signifi cantly in patients with 
heart failure, where they can be used to distinguish dyspnea due to 
heart failure from dyspnea secondary to pulmonary pathology, with a 
high sensitivity in both the acute  as well as in the community settings.(1, 2) 
For BNP a value above 100 pg/mL is indicitave of heart failure, whereas 
there are age-specifi c cut-offs for NT-proBNP - 125 pg/mL for patients 
less than 75 years and 450 pg/mL for patients 75 years and older. Serum 
levels of BNP and NT-proBNP are higher in females, the elderly and 
patients with impaired renal function, even in the absence of myocardial 
disease. Elevated levels are also seen in atrial fi brillation, pulmonary 
embolism, hypertension and hypertrophic cardiomyopathy.(3) It is, 
therefore, not surprising that increased levels have been described in 
patients with heart valve lesions. Although it is now well established that 
raised levels of  BNP and NT-proBNP can be used to predict prognosis 
in patients with heart failure(4) and even in patients with stable coronary 
artery disease without heart failure,(5) knowledge on  the exact meaning 
of increased levels in patients with heart valve lesions is still evolving. 
FINDINGS REGARDING BNP/NT-proBNP AND 
VARIOUS HEART VALVE LESIONS
AORTIC VALVE STENOSIS (AS)
The main indication for aortic valve replacement (AVR) in patients with 
severe AS is the onset of symptoms, notably dyspnea, syncope and 
angina. AVR performed at this stage interrupts the natural course of the 
disease and prevents death. Can BNP and NT-proBNP determination 
add to the management of patients with AS? BNP and NT-proBNP 
levels in patients with aortic valve stenosis have been shown to relate 
to (i) symptoms, (ii) severity of aortic valve stenosis and clinical 
prognosis, and (iii) surgical outcome. In addition, recent data suggest 
that (iv) BNP and NT-proBNP levels may be helpful  in distinguishing 
true severe AS from pseudosevere AS, and may predict outcomes in 
this subgroup of patients.
(i) BNP/NT-proBNP and correlation with symptoms in AS
It is well known that some patients adapt to their functional impairment 
by limiting their activity and, when asked, often deny symptoms such as 
dyspnea or functional impairment. It would, therefore, be useful if a 
biomarker such as BNP or NT-proBNP could distinguish symptomatic 
from asymptomatic patients.  In general, higher serum levels of BNP and 
NT-proBNP refl ect symptoms. Two groups found that a normal BNP 
predicted an asymptomatic state, and thus by implication, patients who 
were not at risk.(6, 7) An NT-proBNP value of 190 pg/mL had a 79% 
sensitivity and 88% specifi city for being symptomatic (i.e. Class II 
dyspnea) in the study by Nessmith et al.,(6) whereas in the study by Lim 
et al.(7)  a BNP level of > 66 pg/ml had a similar sensitivity for being 
symptomatic, namely 84% . However, in an excellent prospective study 
by Bergler-Klein et al.,(8) it was found that BNP levels did not differ 
signifi cantly between patients with Class I and Class II dyspnea – only at 
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increasing levels of dyspnea did the differences become signifi cant. 
Differences in the results seen in these studies may be due to the fact 
that, in the study by Bergler-Klein, all patients had signifi cant aortic valve 
stenosis, whereas in the other studies there was a wide range in the 
severity of stenosis amongst patients.  Another explanation for the 
differences between the cited studies may be that some patients with 
severe AS decrease their functional activity without noticing it, thus 
denying the symptom of dyspnea on clinical evaluation. However, 
Bergler-Klein et al. did fi nd that a BNP level of < 449 pg/ml and an NT-
proBNP level of < 677 pg/ml predicted the absence of development of 
symptoms over the subsequent 6 to 9 months and, even more 
importantly,  BNP or NT-proBNP levels higher than the latter cut-offs 
predicted the occurrence of symptoms within the following 6 to 12 
months.(8) The fact that no functional tests were performed in any of 
the cited studies makes it diffi cult to come to a fi nal conclusion regarding 
the relationship between serum natriuretic levels and symptoms in 
patients with aortic valve stenosis.
(ii) BNP/NT-proBNP, severity of aortic valve stenosis and outcomes
Increased serum BNP and NT-proBNP values refl ect the severity of 
valve stenosis as well as the functional consequences, as NT-proBNP 
levels correlate with mean transvalvular gradients as well as left 
ventricular hypertrophy (as refl ected by mass), LV end-systolic wall 
stress and end-diastolic pressure.(7, 9, 10) An NT-proBNP value of 
550 pg/ml has been shown to predict conventional indications for AVR 
with a sensitivity of 71% and specifi city of 68%.(10) 
Serum BNP and NT-proBNP serum levels not only correlate with 
stenosis severity, but also provide information about clinical prognosis. 
In general, the higher the serum levels of BNP and NT-proBNP, the 
worse the outcome. In the study by Lim et al.,(7) a BNP level of 97 pg/
mL separated the survivors from the non-survivors after one year 
follow-up, irrespective of symptomatic status. These fi ndings are 
supported by Nessmith et al.,(6) who found that no patient with an NT-
proBNP value < 100 pg/mL died during one-year follow-up, whereas 
the one-year mortality rate of patients with values between 100 and 
296 pg/ml, between 296 pg/ml and 819 pg/ml and > 819 pg/ml was 
6%, 34% and 60% respectively. In a study in which patients were 
followed up for a median of 902 days a serum level of NT-proBNP of 
640 pg/ml predicted an adverse outcome in conservatively treated 
patients with severe AS.(11) 
(iii)  BNP in predicting surgical outcomes post aortic valve 
replacement
Evidence is accumulating that pre-operative BNP and NT-proBNP 
levels may predict post-operative outcomes, with higher levels predicting 
poorer outcome. In the study by Vanderheyden et al.,(12) those patients 
who underwent aortic valve replacement based on conventional 
criteria and experienced clinical deterioration post-operatively had a 
signifi cantly higher pre-operative BNP level than those who had no 
complications (399 ± 82 vs. 124 ± 41 pg/ml). These data are supported 
by Bergler-Klein et al.,(8) who found that pre-operative NT-proBNP was 
the only independent predictor of both survival and post-operative 
symptomatic status on multivariate analysis - BNP higher than 369 
pg/ml and NT-proBNP higher than 2745 pg/ml predicted death. 
These fi ndings prompt the question whether BNP or NT-proBNP 
levels should be considered when deciding on valve replacement for 
aortic valve stenosis and, more specifi cally, whether valve replacement 
should be advised on the basis of high circulating levels of natriuretic 
hormones even in the absence of symptoms. The basic pathophysiological 
correlate suggested by these studies is that markedly increased BNP 
and NT-proBNP levels refl ect a lack of left ventricular reserve. Data 
are still lacking, however, and the results of larger studies are awaited 
before such management can be advocated.
(iv) BNP levels and low fl ow, low gradient AS
It is currently accepted that patients with severe AS but reduced 
ejection fraction (EF) have good outcomes after aorta valve replacement 
if the low EF is caused by a high afterload in the absence of true left 
ventricular dysfunction (afterload mismatch). However, patients with 
pseudo AS, as refl ected in low fl ow gradients (<30 mmHg) in the 
presence of low EF (<40%), are not expected to benefi t from AVR to 
the same extent. In contrast, patients with severe true AS and impaired 
left ventricle function (i.e. low EF and low gradients) may benefi t from 
aortic valve replacement if inotropic reserve (increase of 20% in stroke 
volume at peak dobutamine infusion rate) is demonstrated.(13) In a 
recent study by Bergler-Klein et al.,(14) the ability of BNP levels to 
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distinguish between patients with true severe AS and pseudo AS, and 
the predictive value for post-operative outcome in these patients were 
investigated. The authors found that BNP levels were signifi cantly higher 
in true AS than in pseudo AS, yet overlap between the values in the 
two groups precluded using BNP values as an accurate discriminator. 
The most important fi ndings of this study were that a serum BNP value 
of > 550 pg/ml identifi ed patients who had a poor prognosis, whether 
they had true or pseudo AS, no matter whether they were treated 
surgically or medically. Furthermore, even patients with poor contractile 
reserve and true severe AS had a good outcome if the BNP levels were 
< 550 pg/ml. However, the number of patients studied was too small to 
justify a change in current management and more data are needed to 
verify these fi ndings.
In summary, BNP and NT-proBNP serum levels refl ect aortic valve stenosis 
severity, symptomatology and outcome in patients with AS (Table I). In 
general, the higher the serum levels, the more symptomatic the patients, the 
more severe the aortic valve stenosis and the worse the outcome after 
aortic valve replacement.  
MITRAL REGURGITATION (MR)                                     
Currently the decision to perform valve replacement for severe mitral 
regurgitation (MR) primarily relies on the presence of symptoms 
and/or evidence of left ventricular dysfunction, as indicated by echo-
cardiographic parameters such as an ejection fraction below 60% and 
a left ventricular end-systolic (LVES) measurement of > 45 mm. 
Quantitative evaluation of MR adds signifi cantly to outcome prediction, 
but requires additional training and can be cumbersome to perform in 
the busy outpatient setting. Furthermore, measurement of LV systolic 
function (muscle function) can be diffi cult to accurately assess in MR 
due to the load dependency of commonly used parameters such as 
ejection fraction. In severe MR there is signifi cant offl oading of the LV 
into the LA, a low pressure system compared to the aorta, and thus 
early dysfunction of the LV may not be apparent when using these 
parameters. This raises the question whether BNP or NT-proBNP 
could serve as a biochemical parameter to assist the clinician in assessing 
the severity of mitral valve regurgitation and to time valve replacement 
more appropriately. 
Studies on the relationship between BNP and NT-proBNP in mitral 
regurgitation suggest that increased serum levels of BNP and NT-
proBNP in patients with MR may indeed be helpful, as increased serum 
levels (i) refl ect the severity of mitral regurgitation, and refl ect the 
deleterious structural consequences such as left ventricular remodelling 
and increase in left atrium size, (ii) refl ect functional impairment of the 
left ventricle and (iii) predict survival and the occurrence of heart 
failure. In addition, (iv) the change in BNP and NT-proBNP serum levels 
in operated patients identifi es patients who have benefi ted from 
surgery, and separates them from the group in whom no improvement 
is expected to occur, thus suggesting a relationship between serum 
natriuretic peptide levels and LV dysfunction, separate from their 
relationship to degree of regurgitation.
(i) BNP and NT-proBNP and the severity of mitral regurgitation
BNP and NT-proBNP are increased in patients with MR, being higher in 
symptomatic patients than in asymptomatic ones.(15, 16) In the study by 
Sutton et al.(16) a BNP cut-off point of >424 pg/ml had a sensitivity of 
88% in predicting symptoms, compared to a sensitivity of 13% if a left 
ventricular end-systolic diameter (LVES) cut-off of >45 mm was used. 
Strong correlations were shown for BNP and NT-proBNP levels with 
both increased left atrial size or volume, and peak systolic pulmonary 
artery pressure,(16, 17) but they differed with regard to correlations with 
left ventricular dimensions (see below). Serum natriuretric peptides 
were signifi cantly more predictive for identifying symptomatic patients 
than identifying a big LA, the degree of mitral regurgitation (as formally 
quantifi ed using effective regurgitant orifi ce area, regurgitant fraction 
and regurgitant volume) or end-systolic dimensions. 
TABLE 1: Relationship between serum natriuretic peptide levels and aortic valve 
stenosis*
Symptoms >66 pg/ml(7) >190 pg/ml(6)
 >449 pg/ml(8) > 677 pg/ml(8)
Poorer prognosis >97 pg/ml(7) >296 pg/ml(6)
  >640 pg/ml(11)
Poor post-operative outcome 369 pg/ml predicts 2745 pg/ml predicts  
 post-op death(8)  post-op death(8)
Irreversible LV deterioration >550 pg/ml(14) 
NT-proBNP (pg/ml)BNP (pg/ml)
* Discrepancies between reference values may relate to patient populations studied.
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In a follow-up study to evaluate the relationship between increased 
BNP values in MR, and systolic parameters, Detaint et al.(18) studied 
BNP levels in patients with organic and functional MR, and found that 
BNP levels were higher in functional than in organic MR, and that the 
best indicator of BNP levels was end-systolic volume index (ESVI), 
irrespective of the etiology of the valve disease. A BNP level of > 90pg/
ml predicted an end-systolic volume index (ESVI) of >60ml/m2 with an 
odds ratio of 16. Thus, increased BNP levels in patients with both 
organic and functional MR are a marker of a high LV ESVI, and thus of 
LV remodelling, and should raise the concern of undetected alterations 
in LV function.
These fi ndings  suggest that increased serum levels of BNP and NT-proBNP 
in a patient with MR should raise the suspicion of severe disease and 
prompt careful assessment of the grade of regurgitation. The reverse is also 
true - if levels are not increased, it is unlikely that MR is severe.
(ii)  BNP and NT-proBNP as indicators of functional impairment of 
the left ventricle in mitral regurgitation
The next question is whether serum BNP and NT-proBNP levels 
provide any information about left ventricular dysfunction. Some 
relationship between BNP and NT-proBNP levels and LV dimension is 
expected, as its secretion is activated by stretch of the myocardium. In 
the study by Detaint et al.,(17) serum levels weakly correlated with ESVI 
(r =  0.26), and there was a trend for correlation with LV end-diastolic 
volume index (EDVI). However, in the study by Sutton et al.,(16) no 
correlation was found between BNP and NT-proBNP levels and either 
LV end systolic or end-diastolic dimensions. Because LV dilatation in the 
context of severe MR is indicative of LV dysfunction, the absence of a 
strong correlation between BNP and NT-proBNP levels and both end- 
diastolic and end-systolic dimensions raises the question whether the 
natriuretic peptide levels are markers only of severity of MR, rather 
than the functional impairment secondary to the mitral valve lesion. 
Yusoff et al.(19) assessed NT-proBNP as a marker of functional capacity, 
symptoms and cardiac remodelling in patients with severe mitral 
regurgitation and preserved ejection fraction. These authors showed 
that NT-proBNP was an independent marker of functional capacity – it 
showed a very strong negative correlation with VO2max (r = - 0.6) and 
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exercise time (r = - 0.52), and only weakly correlated with conventional 
echocardiographic parameters. These data strongly suggest that NT-
proBNP levels refl ect the impact of MR on cardiac structure and 
function, and are not simply a refl ection of disease severity, degree of 
regurgitation or symptoms. This illustrates an extremely important 
principle – resting measurements did not refl ect LV dysfunction, but the 
failure of contractile reserve only became manifest upon exercise, and 
was predicted by high NT-proBNP levels.  
It seems that increased BNP and NT-proBNP levels do refl ect LV dysfunction, 
which is unmasked by dynamic testing.
(iii)  BNP and NT-proBNP predict survival and occurrence of heart 
failure in mitral regurgitation
The strongest argument for the ability of natriuretic peptides to predict 
LV dysfunction in MR comes from outcomes data, however limited it 
may be at this stage. In a study involving 124 patients it was found that 
a BNP level > 31 pg/ml predicted mortality – 95 ± 5% patients below 
this cut-off were alive after 5 years versus 73 ± 10% above this cut-
off.(17) Using death and new heart failure as end-point, they showed an 
incidence of 42 ± 10% versus 16 ± 7%  for the higher versus the lower 
group. The importance of this observation is highlighted by the fact that 
the only clinical predictors of outcome, namely symptoms and LV 
dysfunction, are present only in a minority of patients, and occur late in 
the disease. Data are currently lacking, but measurement of BNP and 
NT-proBNP may become an independent additional tool in the decision 
making process concerning mitral valve replacement.
(iv)  The change in BNP separated responders from non-responders 
following surgery
The emerging concept with regard to the relationship of BNP to mitral 
regurgitation is thus that it refl ects disease severity to some extent, 
certainly refl ects structural remodelling (LA increase) and increased 
pulmonary artery pressures, and may be a marker of subclinical left 
ventricular dysfunction. More support for the latter comes from 
observations on changes in BNP levels after surgery. In 22 patients 
undergoing mitral valve repair, patients who had a decrease in BNP also 
had a decrease in symptoms and left atrial size, as well as a reversal of 
left ventricular remodelling.(20) Those in whom BNP did not decrease 
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had no decrease in left atrial size, no reversal (and even progression) of 
left ventricular remodelling and had no improvement in symptoms. 
Obviously this is of little practical consequence, and the more important 
question is whether pre-operative BNP values were of assistance in 
identifying the patients that did improve. Unfortunately there were no 
distinguishing features setting the responders apart from the non-
responders. 
In summary, increased BNP and NT-proBNP levels in patients with MR 
suggest a more severe degree of regurgitation, larger left atrial volumes and 
higher pulmonary artery pressures and perhaps larger end-systolic volumes. 
The most impressive data, however, is the correlation of high NT-proBNP 
levels with  impaired functional ability, indicating that left ventricular 
dysfunction could be unmasked by exercise. These data, together with the 
poor survival outcome associated with high BNP levels, suggest that BNP 
and NT-proBNP levels are valuable tools that can alert the clinician to a 
more severe underlying degree of disease and probable left ventricular 
dysfunction, and may in the future become an independent parameter to 
utilize in the assessment of patients for timing of surgery.  
MITRAL STENOSIS (MS)                                                  
All studies concerning serum levels of BNP and NT-proBNP in mitral 
stenosis (MS) report a marked increase in the levels of these peptides 
in MS.(21-23)  There are different reasons for this increase. Many of these 
patients are in atrial fi brillation (AF), which is known to be associated 
with increased levels. In one study, levels in patients with MS and AF 
were nearly twice as high as when patients were in sinus rhythm,(22) 
whereas there was no difference between patients with MS in sinus 
rhythm and AF in the study by Shang et al.(24) In the latter study BNP 
levels remained unchanged 24 hours after mitral valvuloplasty in 
patients who were in AF, whereas they signifi cantly decreased in patients 
who were in sinus rhythm – thus showing the triggering effect of AF on 
BNP secretion. BNP is secreted from the atria, albeit less so than ANP, 
and there is some speculation that left atrial stretch may contribute to 
serum BNP levels. In view of the pulmonary hypertension caused by 
MS, hypertrophy and dilatation of the right ventricle could conceivably 
be a source of BNP, and the correlation with peak pulmonary artery 
pressure (PAP) is very strong in most studies.(21, 22) 
Whatever the source of BNP in MS, BNP levels seem to refl ect the 
severity of the valve lesion, as they strongly correlate with symptoms as 
refl ected in NYHA functional class (r = 0.6) and left atrial size (r = 0.7), 
mitral valve area (r = -0.45) and  mean mitral gradient (r = 0.57).(22) In 
the latter study, serum BNP levels also correlated with right ventricular 
diameter (r = 0.4) and peak pulmonary pressure (r = 0.7), refl ecting 
pulmonary hypertension. It has therefore been suggested that serum 
BNP levels be used for the follow-up of patients with MS as a surrogate 
for echocardiography to monitor the development of pulmonary 
hypertension where echocardiography is not available.(22) However, no 
cut-off value for either BNP or NT-proBNP has been established to 
guide clinical decision making regarding the timing of mitral valve 
replacement or mitral valve balloon valvuloplasty. 
In summary, BNP and NT-proBNP therefore seem to refl ect pulmonary 
hypertension in MS, and may have a role in assessing the development of 
pulmonary hypertension during follow-up where echocardiography is not 
available.
AORTIC VALVE REGURGITATION (AR)                         
Information about serum BNP and NT-proBNP levels in isolated aortic 
valve regurgitation (AR) is scant.(25-27)  BNP and NT-proBNP levels are 
signifi cantly increased in subjects with AR, even in those who are 
asymptomatic. The correlation between serum levels and valve lesion 
severity and left ventricular dysfunction is, however, less clear. In a 
group of 60 patients with a mean age of 22 years, it was found that 
levels increased with an increase in valvular regurgitant severity as 
defi ned by the diameter of the vena contracta(27) – levels increased 
even in mild AR (despite no difference in LV end-diastolic diameter 
compared to control), and were highest in severe AR. These results 
suggest that serum levels do refl ect valve lesion severity. If that were 
true, serum levels would be expected to correlate with conventional 
parameters of LV remodelling such as LVED and LVES. This was indeed 
observed by Eimer et al.,(26) but could not be corroborated in the larger 
study by Gerber et al.(25) However, the latter authors also clearly 
demonstrated that serum levels were signifi cantly higher in symptomatic 
patients when compared to asymptomatic patients, and it was deduced 
that serum levels could not be explained by LV remodelling. The 
observation that serum levels were increased in these patients, who all 
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had an ejection fraction above 50%, was interpreted as probably 
refl ecting early LV dysfunction. Currently there is no information 
regarding the relationship between BNP/NT-proBNP and prognosis.
There is evidence that serum levels (of BNP) in AR may refl ect valve lesion 
severity and, to some extent, LV dysfunction, but no data exist on the 
relationship between BNP or NT-proBNP and mortality outcomes in AR.
MIXED VALVE LESIONS                                                                                            
There are very little data about BNP and NT-proBNP levels in mixed 
valvular disease, but natriuretic peptide levels are usually even higher 
than in isolated heart valve lesions.(28) No information is currently 
available on the relationship between natriuretic hormone levels, 
prognosis and outcomes in mixed heart valve disease.
SUMMARY                                                                           
 Serum levels of BNP and NT-proBNP are increased in patients with 
various forms of heart valve lesions. Most information is available 
for AS and MR and, in both valve diseases, increased serum levels 
predict valve lesion severity to some extent. The meaning of 
increased BNP and NT-proBNP levels in other valve disease such 
as MS, AR and mixed valvular disease is currently not clear.
 Serum levels of BNP and NT-proBNP seem to provide information 
about underlying left ventricular function. High levels predict poorer 
survival in patients with AS and MR who are not operated on, and 
in the case of AS, predict poor post-operative outcomes. 
 Currently no defi nite statement can be made regarding the use of 
natriuretic peptide levels to guide decision making in aortic valve 
replacement. In patients with AS, high levels (BNP > 90 pg/ml and 
NT-proBNP levels of > 190 pg/ml) should at least prompt the 
managing physician to re-evaluate the patient carefully for valve 
stenosis severity, regular review and meticulously search for the 
presence of any conventional indication for aorta valve replacement, 
mindful that some patients may give a poor history about exercise 




 Similarly, high natriuretic peptide levels in patients with MR (BNP 
level of  more than 30 – 50 pg/ml) should prompt careful assessment 
and quantifi cation of the degree of mitral regurgitation (the PISA 
method, for example, may be used to calculate the effective 
regurgitation orifi ce area and regurgitant volume) as well as 
presence of symptoms.
 In MS, increased BNP and NT-proBNP levels refl ect increased 
pulmonary artery pressure, and may be useful to follow patients 
with known MS to detect increased pulmonary pressure if 
echocardiography is not available.
 In AR, BNP and NT-proBNP levels increase with regurgitation 
severity. 
 Future studies will clarify whether serum levels of BNP and NT-
proBNP should be used routinely to guide clinical decision making 
when deciding on the timing of AVR and MVR in patients with AS 
and MR, and will defi ne its role in the evaluation and management 
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